Detalhe da pesquisa
1.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536609
2.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27861874
3.
Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Oncologist
; 20(10): 1111-8, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26341758
4.
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Oncologist
; 20(8): 880-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26099741
5.
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Breast Cancer Res Treat
; 147(3): 599-607, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234842
6.
Anaplasma Species in Ticks Infesting Mammals of Sardinia, Italy.
Animals (Basel)
; 13(8)2023 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37106895
7.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Front Oncol
; 13: 1177681, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441419
8.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol
; 13: 1152123, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37260975
9.
Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice.
Cancer Sci
; 102(3): 509-15, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21175994
10.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Ther Adv Med Oncol
; 13: 17588359211059873, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173816
11.
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
ESMO Open
; 5(4)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817059
12.
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Cancer Biol Ther
; 19(4): 328-334, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336662
13.
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Pharmacogenomics
; 18(8): 821-830, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592202
14.
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Clin Breast Cancer
; 17(1): 11-17, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27561703
15.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Clin Breast Cancer
; 17(8): 601-610.e2, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28479052
16.
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Anticancer Res
; 37(5): 2633-2639, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476838
17.
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Oncotarget
; 8(34): 56921-56931, 2017 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28915642
18.
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice.
Crit Rev Oncol Hematol
; 100: 57-68, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26944782
19.
Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Tumori
; 102(5): 472-480, 2016 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27647231
20.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Oncotarget
; 7(14): 17932-44, 2016 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910921